Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs TKO Group Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while TKO Group Holdings Inc trades at $184.36 (market cap $13.82B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.69% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TKO | |
|---|---|---|
Market Cap | $39.89B | $13.82B |
Sector | Health | Technology |
52-Week High | $491.22 | $224.96 |
52-Week Low | $278.09 | $155.61 |
Enterprise Value | $38.15B | $18.00B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TKO trades at $184.4, down 2.01% today, with a bearish technical signal but strong analyst support. Recent earnings show a Q1 2026 beat but Q3 and Q4 2025 misses, while revenue grew to $4.74B in 2025. The company completed an $800 million share repurchase and announced a dividend, reflecting financial strength. Valuation ratios like P/E of 68.55 are elevated, but profitability margins improved.
Outlook is mixed: bullish analyst consensus with a $234 price target suggests upside, but high valuation and recent earnings volatility pose risks. Growth in live events and partnerships, like the UFC-Paramount deal, offers opportunities, yet execution and market sentiment remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
